Autoimmune muscular pathologies.
The T cell-mediated mechanism responsible for Polymyositis and inclusion Body Myositis and the complement-mediated microangiopathy associated with Dermatomyositis are reviewed. The management of autoimmune myopathies with the presently available immunotherapeutic agents as well as new therapies and ongoing trials are discussed.
Dalakas
M C
MC
Neuromuscular Diseases Section, NINDS, Bethesda, MD, USA. dalakasm@ninds.nih.gov
D015703:Antigens, CD; D001327:Autoimmune Diseases / Q000276:immunology* / Q000628:therapy; D018122:B7-1 Antigen / Q000378:metabolism; D060890:B7-H1 Antigen; D016827:CD8 Antigens / Q000378:metabolism; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D007167:Immunotherapy; D060945:Inducible T-Cell Co-Stimulator Ligand; D008562:Membrane Glycoproteins / Q000378:metabolism; D009468:Neuromuscular Diseases / Q000145:classification / Q000276:immunology* / Q000628:therapy; D010455:Peptides / Q000378:metabolism; D011506:Proteins / Q000378:metabolism
D015703:Antigens, CD; D018122:B7-1 Antigen; D060890:B7-H1 Antigen; C423236:CD274 protein, human; D016827:CD8 Antigens; C498514:ICOSLG protein, human; D007155:Immunologic Factors; D060945:Inducible T-Cell Co-Stimulator Ligand; D008562:Membrane Glycoproteins; D010455:Peptides; D011506:Proteins